Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Impurities & degradation products

An impurity or degradation product above its limit - other than nitrosamines. Unexpected substances in a batch can make it unsafe or less effective, even when the active ingredient is present.

704 FDA drug recalls with this cause, newest first.

Every drug has a specification for how much of each impurity or breakdown product it may contain. These recalls are lots that exceeded one of those limits - often a related compound formed during manufacturing or storage, or an out-of-specification result found during routine stability testing. Nitrosamine impurities are common enough to get their own category; everything else lands here.

Class III · Low risk

CVS pharmacy Original Strength Acid Controller tablets

Failed impurities/degradation specification: An out of specification results has been determined for an individual related substance during stability testing at the 18th month interval for the Famotidine 10 mg Tablet, USP.

Terminated Impurity / degradation Dr. Reddy's Laboratories, Inc. D-1058-2016
Class III · Low risk

Haloperidol Decanoate Injection

Failed Impurities/Degradation Specifications: Firm is recalling product due to an impurity out-of-specification result.

Terminated Impurity / degradation Fresenius Kabi USA, LLC NDC 63323-469-01 D-0818-2016
Class II · Moderate risk

Ondansetron Tablets USP

Failed Impurities/Degradation Specifications; 12 month stability time point

Terminated Impurity / degradation Dr. Reddy's Laboratories, Inc. NDC 56111-153-30 D-0841-2016
Class II · Moderate risk

PerioRx (chlorhexidine gluconate)

Failed impurities/degradation specifications: Out-of-specification result (for multiple batches) for an unknown impurity of Chlorhexidine gluconate.

Terminated Impurity / degradation Akorn, Inc. D-0876-2016
Class II · Moderate risk

Chlorhexidine gluconate

Failed impurities/degradation specifications: Out-of-specification result (for multiple batches) for an unknown impurity of Chlorhexidine gluconate.

Terminated Impurity / degradation Akorn, Inc. NDC 5083-0720-16 D-0875-2016
Class II · Moderate risk

ORIS (chlorhexidine gluconate)

Failed impurities/degradation specifications: Out-of-specification result (for multiple batches) for an unknown impurity of Chlorhexidine gluconate.

Terminated Impurity / degradation Akorn, Inc. D-0874-2016
Class III · Low risk

Ciprofloxacin Ophthalmic Solution

Failed Impurities/Degradation Specifications: Firm voluntarily recalled products due to out-of-specification results for an unknown impurity at or near the expiration (24-month).

Terminated Impurity / degradation Actavis Pharma Inc D-1060-2016
Class II · Moderate risk

Alendronate Sodium Tablets

Failed Impurities/Degradation Specifications: Observed levels of highest unknown impurity exceeding specification limit at the 3 month stability time point.

Terminated Impurity / degradation Sun Pharma Global Fze NDC 41616-638-68 D-0735-2016
Class II · Moderate risk

Paricalcitol Capsules

Failed Impurities/Degradation Specifications: Out of specification test results for impurities during stability testing.

Terminated Impurity / degradation Teva Pharmaceuticals USA NDC 0093-7656-56 D-0774-2016
Class III · Low risk

Clonazepam Tablets

Failed Impurities/Degradation Specifications: out of specification result for known impurity at 6 month timepoint.

Terminated Impurity / degradation Mylan Institutional, Inc. (d.b.a. UDL Laboratories) D-0650-2016